Diagnostic performance of 18F-FDG PET-CT and SPECT for bone metastases from colorectal cancer: a retrospective study
Frontiers in Oncology · 12.06.2026 · 16
DOI: 10.3389/fonc.2026.1829353 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 12.06.2026. Verfasst von Fangyi Gong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The First Affiliated Hospital of Ningbo University, Ningbo, China. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To compare the diagnostic performance of 18F-FDG PET-CT and SPECT whole-body bone imaging for detecting bone metastases in patients with colorectal cancer.
Methods
A retrospective analysis was performed on 118 patients with pathologically confirmed colorectal cancer who underwent both 18F-FDG PET-CT and SPECT whole-body bone imaging within one month during follow-up for newly suspected bone metastases. The cohort included 62 males and 56 females, with a mean age of 59.1 ± 7.6 years. The final diagnosis of bone metastases was established based on comprehensive imaging follow-up, including CT, MRI, SPECT, PET-CT, and clinical progression over more than 6 months. Diagnostic performance was evaluated on a lesion-based basis.
Results
A total of 533 abnormal lesions were detected in 118 patients, including 469 metastatic lesions and 64 benign lesions. PET-CT detected 423 lesions, whereas SPECT detected 398 lesions, with 288 lesions identified by both modalities. PET-CT correctly identified 428 metastatic lesions, yielding a sensitivity of 91.3%, while SPECT identified 280 metastatic lesions, with a sensitivity of 59.7%. Among the benign lesions, PET-CT correctly identified 60 lesions, resulting in a specificity of 93.8%, whereas SPECT correctly identified 30 lesions, with a specificity of 46.9%. The overall diagnostic accuracy of PET-CT and SPECT was 91.6% and 58.2%, respectively.
Conclusion
18F-FDG PET-CT demonstrated significantly higher sensitivity, specificity, and diagnostic accuracy than SPECT for detecting bone metastases from colorectal cancer. PET-CT may provide superior diagnostic value for predominantly osteolytic bone metastases in colorectal cancer, while SPECT remains an important and widely available first-line screening modality in routine clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics, The First Affiliated Hospital of Ningbo University, Ningbo, China.
Zitieren
APA
Gong, F., Fang, Y., Ge, T., Gong, Y., Zhang, B., & Hu, B. (2026). Diagnostic performance of 18F-FDG PET-CT and SPECT for bone metastases from colorectal cancer: a retrospective study. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1829353
Vancouver
Gong F, Fang Y, Ge T, Gong Y, Zhang B, Hu B. Diagnostic performance of 18F-FDG PET-CT and SPECT for bone metastases from colorectal cancer: a retrospective study. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1829353
BibTeX
@article{Gong2026,
author = {Gong, Fangyi and Fang, Yu and Ge, Ting and Gong, Yuanjin and Zhang, Bo and Hu, Baiwen},
title = {Diagnostic performance of 18F-FDG PET-CT and SPECT for bone metastases from colorectal cancer: a retrospective study},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1829353}
}
EUVIMED